Introduction
Peripheral arterial disease (PAD) is an important manifestation of atherosclerosis, which affects .202 million people worldwide, 1 and is associated with cardiovascular events, 2 with increased all-cause and cardiovascular mortality. 3, 4 PAD, despite the advances registered in its treatment, still has a worse prognosis compared with coronary artery disease (CAD) 5 by various factors, including the high rate of instent restenosis, which occurs with an important contribution of the inflammatory response. 6, 7 These negative outcomes have brought in sight the need of biomarkers as predictors of outcomes to ensure better risk stratification, proper selection of treatment approaches, and, if necessary, additional multitarget approaches (such as the endovascular brachytherapy). 8 In recent years, the literature has highlighted the value of systemic inflammation as an important element in the development, progression, and prognosis of atherosclerosis. 9, 10 It is worth to mention that PAD is the atherosclerotic manifestation that shows the greater relationship with systemic inflammation. 11 Several inflammatory markers have been shown to be useful in clinical studies on risk stratification and prognosis of patients with PAD, 12, 13 as well as in those with disease in other vascular beds as cerebral and coronary.
In this article, we reviewed the clinical studies that evaluated the role of inflammatory biomarkers as predictors of outcomes in patients with PAD, with particular emphasis on NLR.
Prognostic value of inflammatory biomarkers in CVDs in general
Multiple inflammatory markers such as C-reactive protein (CRP) and interleukin-6 (IL-6) have been associated with cardiovascular events. 15, 24, 25 CRP is associated with CAD, ischemic stroke, and mortality by vascular and nonvascular causes. 15, 26 The NLR as a biomarker in CAD On CAD, a high NLR is associated with severity of disease, as was evident in a cohort of 3,005 patients undergoing coronary angiography for several indications, in which those with NLR .3 had more advanced obstructive CAD (odds ratio [OR] 2.45, P,0.001) and worse prognosis, with higher rates of major cardiovascular events (hazard ratio [HR] 1.55, P=0.01) within 3 years of follow-up. 27 NLR is a predictor of mortality in patients with ischemic heart disease both in stable CAD 19 and in acute coronary syndrome. 20, 28, 29 A high NLR at admission for acute coronary syndrome is associated with all-cause in-hospital (OR 2.04, P=0.013) and 6-month mortality (OR 3.88, P,0.001). 18 In treated patients, a high pre-intervention NLR was an independent predictor of instent restenosis after percutaneous coronary intervention (OR 1.85, P,0.001), 30 saphenous vein graft failure for those undergoing coronary artery bypass grafting, 31 and cardiovascular mortality. 32 In a meta-analysis of eight cohort studies with patients undergoing myocardial revascularization or coronarography, a high NLR increased about twice the risk of cardiovascular and all-cause mortality. 33 The NLR as a biomarker in cerebrovascular disease
In patients with stroke, the NLR is an independent mortality predictor in the short and long term. [34] [35] [36] An NLR $5.9 at admission was associated with significant functional dependence (OR 6.72, P=0.025) and predicted mortality at 90 days (OR 6.69, P=0.006) after adjusting for potential confounders. 37 In those patients with ischemic stroke who underwent carotid ultrasonography, NLR significantly predicted the degree of carotid stenosis in male patients. 37 In a study in Turkey with patients who presented to the emergency service with cerebrovascular accident (stroke and transient ischemic attack), the NLR was significantly higher in patients who died (P,0.001) and in those with ischemic or hemorrhagic stroke than in those with transient ischemic attack (P,0.001).
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The NLR as a biomarker in other vascular diseases
The role of NLR seems to begin even before the occurrence of any target organ damage, as was demonstrated in a cohort in which a higher NLR level significantly correlated with an increased risk of developing hypertension compared to participants with lower levels (OR 1.23; 95% confidence interval [CI] 1.06, 1.43). 39 In other studies in hypertension, patients with nondipper pattern (that is associated with cardiovascular mortality) presented significantly higher mean NLR than those with dipper pattern (3.1±0.95 vs 1.8±0.52, P,0.001). 40 NLR is also associated with resistant hypertension 41 and other risk factors for atherosclerosis such as metabolic syndrome 42 and diabetes. 43 Table 1 summarizes the clinical studies on the predictive value of inflammatory biomarkers in cardiovascular outcomes.
Inflammatory markers in PAD
Several studies have demonstrated the association between inflammatory markers and the incidence, severity, response to treatment, and prognosis of PAD. [44] [45] [46] [47] CRP was, in a cohort, the strongest nonlipidic predictor of PAD (relative risk [RR] 2.8 for the highest quartile in comparison to the lowest). 44 In other studies, the CRP was a significant predictor of major adverse limb events (target vessel revascularization, amputation, or disease progression) and major cardiovascular events in patients with PAD who have undergone angioplasty or stent 47 and a predictor of mortality. 12, 48 In patients being treated with statins for PAD, the benefit of reducing mortality from all causes and CVD was only significant in those with baseline CRP above the median and not in those with baseline CRP below the median 
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Studies on the role of inflammatory biomarkers in cardiovascular outcomes At the time of coronary angiography procedure A high NLR value (.3) was an independent predictor of CAD severity and predictor of worse clinical outcome.
Arbel et al Abbreviations: AiS, acute ischemic stroke; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CCS, coronary calcium score; CHD, coronary heart disease; Cve, cardiovascular events; hs-CRP, high-sensitive C-reactive protein; iCH, intracerebral hemorrhage; iL-6, interleukin-6; iMT, intima-media thickening; iSR, in-stent restenosis; LM/3vD, left main and/or three-vessel disease; LveF, left ventricular ejection fraction; NHANeS-iii, National Health and Nutrition examination Survey-iii; NLR, neutrophil-lymphocyte ratio; NSTeMi, non-ST-segment elevation myocardial infarction; PAD, peripheral arterial disease; PCi, percutaneous coronary intervention; STeMi, ST-segment elevation myocardial infarction. 
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Studies 13 This result suggests that the benefit of statin is closely related to their anti-inflammatory effect, which is in accordance with the findings in patients with CAD, in which the benefit of statins in survival occurs mainly in subjects with high initial CRP, with fall during treatment, independent of lipid level. 49, 50 It has also been evident in the finding that statin mitigated plaque inflammation, measured by noninvasive imaging with 18F-fluorodeoxyglucose positron emission tomography. 51, 52 And, even in apparently healthy individuals, with elevated baseline high-sensitive CRP, treatment with statin reduced significantly the incidence of major cardiovascular events. 53 Another inflammatory marker associated with PAD and its progression is the IL-6. 46, 54 In a cohort of 12 years of follow-up, IL-6 was the inflammatory marker that showed the strongest and consistent predictive value for progression of PAD. 54 And, in patients with established PAD, persistently high IL-6 levels are associated with faster functional decline 25 and greater severity of disease with critical limb ischemia (CLI).
46 Table 2 summarizes the clinical studies on the predictive value of general inflammatory biomarkers (other than NLR) in PAD.
The particular role of NLR as a prognostic marker in PAD PAD severity
In PAD, a high NLR is associated with increased severity of disease, 55, 56 as was evident in a retrospective cohort of 2,121 patients with PAD in which CLI occurred significantly more in the group with a high NLR (48.5% vs 24.3%, P,0.001). 56 In another study including 1,995 patients with PAD, the increase in NLR was associated with a significant increase in CLI rates (20.4%, 26.1%, and 36.1% for the first, second, and third tertiles, respectively). 55 
Response to treatment and prognosis
In patients who initially received conservative therapy for CLI, a high NLR was an independent predictive factor for amputation and was associated with lower amputation-free survival. 57, 58 A high NLR was a risk factor for amputation within 30 days in patients who underwent initial embolectomy for acute limb ischemia 31 and an independent predictor of graft failure (occlusion or ipsilateral amputation) in those undergoing infrainguinal bypass grafting. 59 
Mortality
A high NLR not only predicts disease severity and response to treatment but also is a predictor of mortality. 60 In patients followed for PAD, a high NLR predicted independently long-term cardiovascular mortality (HR 2.04, P=0.004). 60 A high NLR at admission for chronic CLI is associated with increased mortality. 61 In treated patients, a high pre-intervention NLR was an independent predictor of mortality in those who have undergone infrapopliteal percutaneous intervention for CLI (HR 1.95, P,0.03) . 62 And, even in those undergoing elective revascularization, a high preoperative NLR was independently associated with increased mortality. 63, 64 
Potential mechanism underlying NLR role in PAD and atherosclerosis in general
Despite substantial epidemiological evidence of the predictive role of NLR in atherosclerotic manifestations, there is a lack of pathophysiological body for such findings. This derived marker is an imbalance of inflammatory cells (disproportionate dominance of neutrophils over lymphocytes), and it may be a reflection of a deeper imbalance in the immunologic response, with the dominance of effectors cells over the regulatory cells, mainly CD4 + T-helper cells. 65, 66 Some studies have described the domain of subtype T-helper 17 over the regulatory T-cells, resulting in the activation of the interleukin-17 axis that is in turn associated with vascular dysfunction, progression of atherosclerosis, and vascular events. 65, 67, 68 Several other mechanisms may be involved in the link between NLR and atherosclerosis, including endothelial dysfunction 69, 70 and oxidative stress. 71 However, in light of the current literature, there are no sufficient data to support the formulation of a conceptual or pathophysiologic model linking the two. Despite this gap, we know that atherosclerosis is mainly an inflammatory disease, 72 and currently effective therapies, particularly statins, are associated with decreasing inflammatory response. 49, 51, 52, 73 The most accurate understanding of the mechanisms underlying this emerging evidence from clinical studies should be a substrate of a call to action for future studies in basic science, translational, experimental, and clinical levels.
Concerns and limitations of the NLR as a cardiovascular biomarker
Some concerns arise regarding the potential use of NLR as a cardiovascular biomarker. NLR is increased in other situations such as nonalcoholic fatty liver disease, metabolic syndrome, psoriasis, and cancer. 42, 74, 75 All these conditions share in common an inflammatory or immune response in a given point of their pathogenesis, and interestingly, most of these have been also associated with CVDs as described During baseline assessment Higher hs-CRP tertiles at baseline were significantly associated with decreased ABPI at baseline and at 12 months, reflecting severity. Furthermore, serum hs-CRP was associated with death and/or any cardiovascular event during a median 24-month follow-up period.
Abbreviations: ABi, ankle-brachial index; ABPi, ankle-brachial pressure index; CLi, critical limb ischemia; CRP, C-reactive protein; CvD, cardiovascular disease; evT, endovascular therapy; hs-CRP, high-sensitive C-reactive protein;
iCAM-1, intercellular adhesion molecule-1; iL-6, interleukin-6; MACe, major adverse cardiovascular events (stroke, myocardial infarction, or death); MALe, major adverse limb events (femoropopliteal interventions); NA, not applicable; NLR, neutrophil-lymphocyte ratio; OR, odds ratio; PAD, peripheral arterial disease; PTA, percutaneous transluminal angioplasty. 
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Studies on the role of inflammatory biomarkers in cardiovascular outcomes by Ganzetti et al 76 in his recent review. Despite being a nonspecific marker, NLR has shown consistency in predicting outcomes in atherosclerotic diseases, [16] [17] [18] [19] 23, [33] [34] [35] [36] [58] [59] [60] and even in the nationally representative sample of American subjects, NLR was significantly higher in those who reported diabetes, CVD, and smoking than in subjects who did not. 23 In addition, NLR has a good correlation with other inflammatory markers such as CRP, 77 presenting even better performance as a biomarker in specific conditions. 78 There are some important limitations of this study. The first is the use of different cutoff values in different studies and the scarcity of published works validating the normality value in the general population. However, as we just underlined, most studies in atherosclerosis found a higher cutoff than the average NLR value (2.15) found in the only existing study in the general population, 23 which suggests the plausibility of the association found in those studies. The second is the absence of studies that have validated the normality value for specific populations. This point is critical because as a derived ratio, it is, of course, affected by changes either in the numerator or the denominator. For example, subjects who have a relative constitutional lymphopenia would easily be classified as having a high NLR, without necessarily an increased inflammatory activity. So, it is prone to potential bias that could lead to false-positive associations. The third is relative to the paucity of studies clarifying the mechanisms underlying the association between NLR and atherosclerosis.
Conclusion and future directions
From the available evidence, it is very likely that the presence of a high NLR has predictive value for future vascular events in asymptomatic and symptomatic subjects. This simple, fast, and widely available biomarker can offer an additional noninvasive tool for risk stratification to assess the severity, response to treatment and prognosis of PAD.
More studies are necessary to know and clarify the role of NLR as an additional tool in PAD. This is reinforced because its role has been reproducible and consistent in other vascular beds as cerebral and coronary, especially in the current scenario of growing recognition of various diseases, with chronic inflammatory component as risk factors for atherosclerosis.
Further studies should be addressed to establish the normality value for specific populations to clarify the underlying mechanisms in atherogenesis and should be designed to 
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Paquissi assess the effectiveness of anti-inflammatory therapies using the fall of NLR as a surrogate outcome and assess its role to guide therapy.
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